Alnylam Pharmaceuticals Down 8.1%, Worst Performer on Nasdaq 100
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: NASDAQ.COM
- Poor Stock Performance: Alnylam Pharmaceuticals is down 8.1% today, making it the worst performer in the Nasdaq 100, reflecting market concerns about its future growth potential.
- Year-to-Date Review: Year-to-date, Alnylam's performance has declined by approximately 7.9%, indicating ongoing challenges the company faces in the competitive biopharmaceutical market.
- Market Dynamics: In contrast, Insmed's stock is down 3.7%, while Palantir Technologies is up 1.9%, highlighting differing market reactions to various companies that may influence investor asset allocation strategies.
- Investor Sentiment: The continued decline of Alnylam Pharmaceuticals may weaken investor confidence in its future performance, potentially impacting shareholder value and market positioning.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ALNY with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ALNY
Wall Street analysts forecast ALNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALNY is 500.28 USD with a low forecast of 351.00 USD and a high forecast of 570.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 349.580
Low
351.00
Averages
500.28
High
570.00
Current: 349.580
Low
351.00
Averages
500.28
High
570.00
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alnylam Pharmaceuticals Q4 2025 Earnings Outlook
- Earnings Expectations: Alnylam anticipates total Q4 2025 revenue of $1.16 billion with adjusted earnings per share of $1.50, indicating sustained growth potential in the biotech sector.
- Amvuttra Sales Surge: In Q3 2025, Amvuttra's sales skyrocketed by 162% year-over-year, primarily driven by rapid adoption in the transthyretin cardiac amyloidosis (ATTR-CM) indication, which is expected to boost Q4 performance.
- Market Performance: Although Alnylam's market share remains limited in international markets, particularly in Q4, stronger growth is anticipated in Germany and Japan in 2026, reflecting the company's strategic positioning in global markets.
- Pipeline Updates: Alnylam is expected to provide updates on its pipeline progress in the upcoming earnings report, including the initiation of a Phase 3 study for hereditary ATTR with polyneuropathy and a Phase 2 trial for Alzheimer's disease, showcasing ongoing R&D advancements.
Continue Reading
Marvell Technology and Others May Join S&P 500
- Inclusion Candidates: According to a report by Stephens, large-cap stocks like Marvell Technology, Vertiv, Strategy, Reddit, and Alnylam Pharmaceuticals meet the eligibility criteria for S&P 500 inclusion, drawing investor attention.
- Performance Expectations: Newly added S&P 500 constituents typically perform strongly post-announcement, prompting investors to closely monitor these candidates ahead of the U.S. Index Committee's reshuffle scheduled for Friday.
- Sector Dynamics Impact: Communication services and financials are underweight in the index relative to their market size, increasing the likelihood of Reddit and SoFi Technologies' inclusion, with the latter being the most liquid financial candidate.
- M&A Activity Potential: Data center infrastructure provider Vertiv could benefit from pending M&A activity that may create vacancies in the S&P 500, further enhancing its chances of inclusion.
Continue Reading